Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study
Krishnarajah Nirantharakumar and colleagues present results from a cohort of women with gestational diabetes and identify these as a target group for preventative interventions for cardiovascular disease and type 2 diabetes.
Vyšlo v časopise:
Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study. PLoS Med 15(1): e32767. doi:10.1371/journal.pmed.1002488
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002488
Souhrn
Krishnarajah Nirantharakumar and colleagues present results from a cohort of women with gestational diabetes and identify these as a target group for preventative interventions for cardiovascular disease and type 2 diabetes.
Zdroje
1. Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med. 2012;29(7):844–54. doi: 10.1111/j.1464-5491.2011.03541.x 22150506
2. Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010;36(6 Pt 2):628–51. doi: 10.1016/j.diabet.2010.11.014 21163426
3. Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: differences between the current international diagnostic criteria and implications of switching to IADPSG. J Diabetes Complications. 2015;29(4):544–9. doi: 10.1016/j.jdiacomp.2015.03.006 25837380
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81–90. doi: 10.2337/dc14-S081 24357215
5. Farrar D, Simmonds M, Griffin S, Duarte A, Lawlor DA, Sculpher M, et al. The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technol Assess. 2016;20(86):1–348. doi: 10.3310/hta20860 27917777
6. Simmons D, Rowan J, Reid R, Campbell N, National GDM Working Party. Screening, diagnosis and services for women with gestational diabetes mellitus (GDM) in New Zealand: a technical report from the National GDM Technical Working Party. N Z Med J. 2008;121(1270):74–86. 18364758
7. Simmons D. Diabetes and obesity in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(1):25–36. doi: 10.1016/j.bpobgyn.2010.10.006 21247811
8. Rowan JA, Budden A, Ivanova V, Hughes RC, Sadler LC. Women with an HbA of 41–49 mmol/mol (5.9–6.6%): a higher risk subgroup that may benefit from early pregnancy intervention. Diabet Med. 2016;33(1):25–31. doi: 10.1111/dme.12812 26031320
9. Kramer CK, Swaminathan B, Hanley AJ, Connelly PW, Sermer M, Zinman B, et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care. 2014;37(12):3262–9. doi: 10.2337/dc14-1529 25231898
10. Sokup A, Ruszkowska-Ciastek B, Walentowicz-Sadlecka M, Grabiec M, Rosc D. Gestational diabetes mellitus worsens the profile of cardiometabolic risk markers and decrease indexes of beta-cell function independently of insulin resistance in nondiabetic women with a parental history of type 2 diabetes. J Diabetes Res. 2014;2014:743495. doi: 10.1155/2014/743495 25097861
11. Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. Diabet Med. 2014;31(3):292–301. doi: 10.1111/dme.12382 24341443
12. Li W, Zhang S, Liu H, Wang L, Zhang C, Leng J, et al. Different associations of diabetes with beta-cell dysfunction and insulin resistance among obese and nonobese Chinese women with prior gestational diabetes mellitus. Diabetes Care. 2014;37(9):2533–9. doi: 10.2337/dc14-0573 24914241
13. Kusunoki Y, Katsuno T, Nakae R, Watanabe K, Ochi F, Tokuda M, et al. Insulin resistance and beta-cell function influence postprandial blood glucose levels in Japanese patients with gestational diabetes mellitus. Gynecol Endocrinol. 2015;31(12):929–33. doi: 10.3109/09513590.2015.1075498 26288254
14. Lekva T, Bollerslev J, Godang K, Roland MC, Friis CM, Voldner N, et al. Beta-cell dysfunction in women with previous gestational diabetes is associated with visceral adipose tissue distribution. Eur J Endocrinol. 2015;173(1):63–70. doi: 10.1530/EJE-15-0153 25877991
15. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25(10):1862–8. 12351492
16. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–9. doi: 10.1016/S0140-6736(09)60731-5 19465232
17. Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31(8):1668–9. doi: 10.2337/dc08-0706 18487472
18. Goueslard K, Cottenet J, Mariet AS, Giroud M, Cottin Y, Petit JM, et al. Early cardiovascular events in women with a history of gestational diabetes mellitus. Cardiovasc Diabetol. 2016;15:15. doi: 10.1186/s12933-016-0338-0 26817691
19. Tobias DK, Stuart JJ, Li S, Chavarro J, Rimm EB, Rich-Edwards J, et al. Association of history of gestational diabetes with long-term cardiovascular disease risk in a large prospective cohort of US women. JAMA Intern Med. 2017;177(12):1735–42. doi: 10.1001/jamainternmed.2017.2790 29049820
20. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9 20609967
21. Keteepe-Arachi T, Sharma S. Underestimating risk in women delays diagnosis of CVD. Practitioner. 2016;260(1791):11–5. 27214974
22. Kalra B, Gupta Y, Kalra S. Gestational diabetes mellitus (GDM) follow up: as simple as ABCDE. Diabetes Res Clin Pract. 2015;107(2):e5–6. doi: 10.1016/j.diabres.2014.12.006 25624178
23. Smith BJ, Cinnadaio N, Cheung NW, Bauman A, Tapsell LC, van der Ploeg HP. Investigation of a lifestyle change strategy for high-risk women with a history of gestational diabetes. Diabetes Res Clin Pract. 2014;106(3):e60–3. doi: 10.1016/j.diabres.2014.09.035 25451910
24. Chang Y, Chen X, Cui H, Zhang Z, Cheng L. Follow-up of postpartum women with gestational diabetes mellitus (GDM). Diabetes Res Clin Pract. 2014;106(2):236–40. doi: 10.1016/j.diabres.2014.08.020 25271112
25. Paez KA, Eggleston EM, Griffey SJ, Farrar B, Smith J, Thompson J, et al. Understanding why some women with a history of gestational diabetes do not get tested for diabetes. Womens Health Issues. 2014;24(4):e373–9. doi: 10.1016/j.whi.2014.04.008 24981396
26. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. London: National Institute for Health and Care Excellence; 2015 [cited 2017 Aug 4]. Available from: https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-51038446021.
27. University College London. THIN database. London: University College London; 2017 [cited 2017 Dec 3]. Available from: https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database.
28. Office for National Statistics. Ethnicity and national identity in England and Wales: 2011. Newport: Office for National Statistics; 2012 [cited 2017 Aug 4]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/articles/ethnicityandnationalidentityinenglandandwales/2012-12-11.
29. Health and Social Care Information Centre. NHS Digital. 2017 [cited 2017 Oct 12]. Available from: https://www.gov.uk/government/organisations/health-and-social-care-information-centre.
30. British National Formulary. BNF publications. 2017 [cited 2017 Aug 4]. Available from: https://www.bnf.org/.
31. NHS Digital. Information and technology for better health and care. London: National Health Service; 2017 [cited 2017 Oct 24]. Available from: https://digital.nhs.uk/.
32. World Health Organization. Noncommunicable diseases global monitoring framework: indicator definitions and specifications. Geneva: World Health Organization; 2014 [cited 2017 Dec 4]. Available from: http://www.who.int/nmh/ncd-tools/indicators/GMF_Indicator_Definitions_FinalNOV2014.pdf?ua=1.
33. StataCorp. Stata Statistical Software. Release 14. College Station (Texas) StataCorp; 2015.
34. National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. London: National Institute for Health and Care Excellence; 2008.
35. Fadl H, Magnuson A, Ostlund I, Montgomery S, Hanson U, Schwarcz E. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case-control study. BJOG. 2014;121(12):1530–6. doi: 10.1111/1471-0528.12754 24762194
36. Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care. 2006;29(9):2078–83. doi: 10.2337/dc05-2482 16936156
37. Bentley-Lewis R, Powe C, Ankers E, Wenger J, Ecker J, Thadhani R. Effect of race/ethnicity on hypertension risk subsequent to gestational diabetes mellitus. Am J Cardiol. 2014;113(8):1364–70. doi: 10.1016/j.amjcard.2014.01.411 24576544
38. Kim C, Tabaei BP, Burke R, McEwen LN, Lash RW, Johnson SL, et al. Missed opportunities for type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus. Am J Public Health. 2006;96(9):1643–8. doi: 10.2105/AJPH.2005.065722 16873752
39. Han S, Middleton PF, Bubner TK, Crowther CA. Women’s views on their diagnosis and management for borderline gestational diabetes mellitus. J Diabetes Res. 2015;2015:209215. doi: 10.1155/2015/209215 25785278
40. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktary WM, et al. Screening and diagnosing gestational diabetes mellitus. Evid Rep Technol Assess (Full Rep). 2012;210:1–327.
41. Vurbic D, Harder VS, Redner RR, Lopez AA, Phillips JK, Higgins ST. Co-occurring obesity and smoking among U.S. women of reproductive age: associations with educational attainment and health biomarkers and outcomes. Prev Med. 2015;80:60–6. doi: 10.1016/j.ypmed.2015.05.020 26051199
42. Wendland EM, Pinto ME, Duncan BB, Belizan JM, Schmidt MI. Cigarette smoking and risk of gestational diabetes: a systematic review of observational studies. BMC Pregnancy Childbirth. 2008;8:53. doi: 10.1186/1471-2393-8-53 19077324
43. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5. 22828580
44. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–9. doi: 10.1210/jc.2008-0772 18826999
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2018 Číslo 1
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Zástava srdce u pacienta se střelnými ranami – kazuistika
- Statinová intolerance
Najčítanejšie v tomto čísle
- Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study
- Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: A retrospective cohort
- PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults